Investments	6 Months Ended
Jun. 30, 2026
Investments, All Other Investments [Abstract]
Investments	Investments The Company’s sole investment is in the form of equity securities in a single private entity, Eleison Pharmaceuticals, Inc. (“Eleison”). The Company entered into a strategic collaboration agreement with Eleison and received such equity securities as remuneration for services rendered. The investment is initially valued at $116,670 (see Note 4). The Company has elected the measurement alternative and, accordingly, the investment is carried at its estimated fair value calculated as its cost less any impairment charges until such time as there is evidence of an orderly transaction. As of June 30, 2026, no fair value adjustments have been recognized, nor have there been any impairment charges. This investment is considered a financial asset that is measured at fair value on a non-recurring basis.

Investments

6 Months Ended

Jun. 30, 2026

Investments, All Other Investments [Abstract]

The Company’s sole investment is in the form of equity securities in a single private entity, Eleison Pharmaceuticals, Inc. (“Eleison”). The Company entered into a strategic collaboration agreement with Eleison and received such equity securities as remuneration for services rendered. The investment is initially valued at $116,670 (see Note 4). The Company has elected the measurement alternative and, accordingly, the investment is carried at its estimated fair value calculated as its cost less any impairment charges until such time as there is evidence of an orderly transaction. As of June 30, 2026, no fair value adjustments have been recognized, nor have there been any impairment charges. This investment is considered a financial asset that is measured at fair value on a non-recurring basis.